Abstract: Compounds of the formula I in which X, Y, R1, R1?, R2, R3 have the meanings indicated in Claim 1, are inhibitors of cell proliferation and can be employed for the treatment of tumors.
Type:
Grant
Filed:
November 14, 2006
Date of Patent:
April 17, 2012
Assignee:
Merck Patent Gesellschaft MIT Meschraenkter Haftung
Inventors:
Oliver Schadt, Dieter Dorsch, Claus Fittschen, Matthias Grell
Abstract: The invention relates to compositions, conjugates and methods comprising pyridazine compounds and cholinesterase inhibitors for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.
Type:
Grant
Filed:
April 27, 2007
Date of Patent:
April 17, 2012
Assignee:
Northwestern University
Inventors:
D. Martin Watterson, Linda Van Eldik, Wenhui Hu
Abstract: An object of the present invention is to provide a novel semiconductor device which is excellent in stability, uniformity, reproducibility, heat resistance, durability and the like, and can exert excellent transistor properties. The semiconductor device is a thin-film transistor, and this thin-film transistor uses, as an active layer, a polycrystalline oxide semiconductor thin film containing In and two or more metals other than In and having an electron carrier concentration of less than 1×1018/cm3.
Abstract: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds for example, indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, which act as ligands for the ?7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
Type:
Grant
Filed:
June 17, 2011
Date of Patent:
April 17, 2012
Assignee:
Memory Pharmaceuticals Corporation
Inventors:
Wenge Xie, Brian Herbert, Jianguo Ma, Truc Minh Nguyen, Richard Schumacher, Carla Maria Gauss, Ashok Tehim
Abstract: A method of automatically counting a number of inclusions by eliminating the effects of shrinkage cavities in the conventional method and securing a high correlation with a value measured by a skilled worker and a casting mold for obtaining a cast sample used for the same are provided. A method of measurement of a number of nonmetallic inclusions comprising capturing an image of a rectangular fracture surface of a cast sample consisting of an aluminum alloy by a CCD camera or other image capturing means, processing the image captured by the image capturing means for color density, digitalizing the processed image by a predetermined threshold value, and counting the number of pixel clusters of a predetermined size or more, the method characterized by detecting the end edges of the short sides of the rectangular fracture surface before the capturing of its image and automatically setting measurement regions of an area of ¼ to ? of the area of the fracture surface at the two ends of the fracture surface.
Type:
Grant
Filed:
March 7, 2008
Date of Patent:
April 10, 2012
Assignees:
Toyota Jidosha Kabushiki Kaisha, Nippon Light Metal Company, Ltd.
Abstract: The multiphase combination preparation for oral therapy of dysfunctional uterine bleeding and for oral contraception contains a first phase consisting of 2 daily dosage units, each containing 3 mg of estradiol valerate or <3 mg of estradiol; a second phase consisting of a first group of 5 daily dosage units, each consisting of a combination of 2 mg of dienogest with 2 mg of estradiol valerate or <2 mg of estradiol, and a second group consisting of 17 daily dosage units, each consisting of a combination of 3 mg of dienogest with 2 mg of estradiol valerate or <2 mg of estradiol; a third phase consisting of 2 daily dosage units, each containing 1 mg of estradiol valerate or <1 mg of estradiol; and another phase consisting of 2 daily dosage units of a pharmaceutically harmless placebos.
Type:
Grant
Filed:
December 12, 2006
Date of Patent:
April 10, 2012
Assignee:
Bayer Pharma Aktiengesellschaft
Inventors:
Susan Zeun, Pol Boudes, Angelo Secci, Jan Nedrikat, Holger Zimmermann
Abstract: An oxide sintered body including an indium element (In), a gallium element (Ga), a zinc element (Zn) and a tin element (Sn), and including a compound shown by Ga2In6Sn2O16 or (Ga,In)2O3.
Abstract: The present invention aims to provide an organic thin film transistor that is superior in stability in the atmosphere and that has a high operation speed.
Abstract: A closure with an additive reservoir is mounted on a container for a consumable liquid. The closure has a base, which includes the additive reservoir; a spout mounted on the base; a plunger positioned in the additive reservoir, and an outer cap. Upon advancing the plunger, an additive in the reservoir is released into the consumable liquid after the additive or plunger ruptures or otherwise opens a barrier provided by a foil, membrane or plug. Upon moving the spout from a first position on the base to a second position, a passageway through the base is opened and the consumable liquid flows to the consumer without having to remove the closure. The additive chamber is mounted in a support column of the base with the passageway for the consumable liquid being disposed between the additive chamber and the support column. In a preferred embodiment the additive is the sole pressure link between the plunger and barrier.
Type:
Grant
Filed:
December 22, 2008
Date of Patent:
April 10, 2012
Inventors:
Eric K. Lizerbram, Gerry R. Krippner, Todd G. Buchholz, William S. Anapoell
Abstract: An amorphous transparent conductive film containing as a main component a six oxygen-coordinated metal oxide, and satisfying, in a radial distribution function (RDF) obtained by an X-ray scattering measurement, a relationship of A/B>1, providing that the maximum value of RDF at an interatomic distance of from 0.30 nm to 0.36 nm is A and the maximum value of RDF at an interatomic distance of from 0.36 nm to 0.42 nm is B.
Type:
Grant
Filed:
March 7, 2006
Date of Patent:
April 10, 2012
Assignee:
Idemitsu Kosan Co., Ltd.
Inventors:
Yukio Shimane, Kazuyoshi Inoue, Masato Matsubara, Nobuo Tanaka, Tokie Tanaka, legal representative, Shigekazu Tomai, Koki Yano, Shigeo Matsuzaki
Abstract: Novel compounds of the formula (I), in which W, T, R1, R2, R3, R4, R5 and R6 have the meanings indicated in Patent Claim (1), are suitable as antidiabetics.
Type:
Grant
Filed:
September 27, 2007
Date of Patent:
April 10, 2012
Assignee:
Merck Patent Gesellschaft mit beschrankter Haftung
Inventors:
Markus Klein, Rolf Gericke, Norbert Beier, Bertram Cezanne, Christos Tsaklakidis, Werner Mederski
Abstract: The present invention relates to oxonium salts having [(Ro)3O]+ cations and sulfonium salts having [(Ro)3S]+ cations, where Ro denotes straight-chain or branched alkyl groups having 1-8 C atoms or phenyl which is unsubstituted or substituted by Ro, ORo, N(Ro)2, CN or halogen, and anions selected from the group of [PFx(CyF2y+1?xHz)6?x]? anions, where 2?x?5, 1?y?8 and 0?z?2y+1, or anions selected from the group of [BFn(CN)4?n]? anions, where n=0, 1, 2 or 3, or anions selected from the group of [(Rf1SO2)2N]? anions or anions selected from the group of [BFWRf24?w]? anions, to processes for the preparation thereof, and to the use thereof, in particular for the preparation of ionic liquids.
Type:
Grant
Filed:
October 20, 2010
Date of Patent:
April 3, 2012
Assignee:
Merck Patent Gesellschaft Mit Beschrankter Haftung
Inventors:
Nikolai (Mykola) Ignatyev, German Bissky, Helge Willner
Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
Type:
Grant
Filed:
November 9, 2005
Date of Patent:
April 3, 2012
Assignees:
Athersys, Inc., Oregon Health and Science University
Inventors:
Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
Abstract: The invention concerns a bore screen comprising a plurality of perforated rigid tubular modules (1) impermeably connected in series by ball joint means (2), allowing an extracted fluid to flow though all of the elements in series and allowing the consecutive elements to move freely relative to one another, tilting in all directions.
Abstract: An organic thin film transistor including a substrate having thereon at least three terminals of a gate electrode, a source electrode and a drain electrode, an insulator layer and an organic semiconductor layer, with a current between a source and a drain being controlled upon application of a voltage to the gate electrode, wherein the organic semiconductor layer includes a specified organic compound having an acetylene or olefin structure in the center thereof; and an organic thin film light emitting transistor utilizing an organic thin film transistor, wherein the organic thin film transistor is one in which light emission is obtained utilizing a current flowing between the source and the drain, and the light emission is controlled upon application of a voltage to the gate electrode, and is made high with respect to the response speed and has a large ON/OFF ratio, are provided.
Abstract: The present invention relates firstly to HF/fluoride-free etching and doping media which are suitable both for the etching of inorganic layers and also for the doping of underlying layers. The present invention secondly also relates to a process in which these media are employed.
Abstract: The invention relates to a multilayer structure comprising at least two layers: a layer, referred to as the inner layer, intended to be in contact with a fluid, comprising a composition comprising at least one polymer and not comprising any copper, and a layer, referred to as the outer layer, intended to be in contact with the air, comprising a composition containing at least one polymer and at least one copper-based stabilizer. The invention also relates to a pipe comprising such a multilayer structure, and also to its use for transporting or storing fluids.
Type:
Grant
Filed:
March 2, 2009
Date of Patent:
April 3, 2012
Assignee:
Arkema France
Inventors:
Vincent Ferreiro, Thibaut Montanari, Fabrice Montezin
Abstract: The invention relates to a catalyst that comprises a metal M from the group of platinum, at least one promoter X1 that is selected from the group that consists of tin, germanium, and lead, and optionally at least one promoter X2 that is selected from the group that consists of gallium, indium and thallium, a halogenated compound and a porous substrate, in which the atomic ratio X1/M and optionally X2/M is between 0.3 and 8, the Hir/M ratio that is measured by hydrogen adsorption is greater than 0.40, and the bimetallicity index BMI that is measured by hydrogen/oxygen titration is greater than 108. The invention also relates to the process for the preparation of this catalyst and a reforming process using said catalyst.
Type:
Grant
Filed:
December 7, 2007
Date of Patent:
April 3, 2012
Assignee:
IFP Energies Nouvelles
Inventors:
Pierre-Yves Le Goff, Fabienne Le Peltier, Jean Giraud, Sylvie Lacombe, Christophe Chau
Abstract: The invention relates to tricyclic aromatics of the general formula I in which A1, A2, A3, A4, Q1-Q2, R1, R2, X1, X2, X3, Z1, Z2, Z3, Z4, q, r, s, t and u have the meaning indicated, and to the use thereof as components of liquid-crystalline media and to an electro-optical display element containing same.
Type:
Grant
Filed:
December 29, 2006
Date of Patent:
April 3, 2012
Assignee:
Merck Patent Gesellschaft MIT Beschraenkter Haftung
Inventors:
Rudolf Eidenschink, Holger Kretzschmann
Abstract: The invention relates to salts having alkoxytris(fluoroalkyl)borate anions which on the one hand are used for the synthesis of ionic liquids, but on the other hand can be employed per se as ionic liquid, and to processes for the preparation thereof.
Type:
Grant
Filed:
March 2, 2010
Date of Patent:
March 27, 2012
Assignee:
Merck Patent GmbH
Inventors:
Nikola (Mykola) Ignatyev, Urs Welz-Biermann, Maik Finze, Eduard Bernhardt, Helge Willner